ArticleSensors (Basel, Switzerland)2018
LSPR and Interferometric Sensor Modalities Combined Using a Double-Clad Optical Fiber.
Article in Sensors (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- Label-free optical biosensors in the pandemic era.Nanophotonics (Berlin, Germany) · 2022Review
- In Situ Synthesis of Gold Nanoparticles in Layer-by-Layer Polymeric Coatings for the Fabrication of Optical Fiber Sensors.Polymers · 2022Article
- Composite-Scattering Plasmonic Nanoprobes for Label-Free, Quantitative Biomolecular Sensing.Small (Weinheim an der Bergstrasse, Germany) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report on characterization of an optical fiber-based multi-parameter sensor concept combining localized surface plasmon resonance (LSPR) signal and interferometric sensing using a double-clad optical fiber. The sensor consists of a micro-Fabry-Perot in the form of a hemispherical stimuli-responsive hydrogel with immobilized gold nanorods on the facet of a cleaved double-clad optical fiber. The swelling degree of the hydrogel is measured interferometrically using the single-mode inner core, while the LSPR signal is measured using the multi-mode inner cladding. The quality of the interferometric signal is comparable to previous work on hydrogel micro-Fabry-Perot sensors despite having gold nanorods immobilized in the hydrogel. We characterize the effect of hydrogel swelling and variation of bulk solution refractive index on the LSPR peak wavelength. The results show that pH-induced hydrogel swelling causes only weak redshifts of the longitudinal LSPR mode, while increased bulk refractive index using glycerol and sucrose causes large blueshifts. The redshifts are likely due to reduced plasmon coupling of the side-by-side configuration as the interparticle distance increases with increasing swelling. The blueshifts with increasing bulk refractive index are likely due to alteration of the surface electronic structure of the gold nanorods donated by the anionic polymer network and glycerol or sucrose solutions. The recombination of biotin-streptavidin on gold nanorods in hydrogel showed a 7.6 nm redshift of the longitudinal LSPR. The LSPR response of biotin-streptavidin recombination is due to the change in local refractive index (RI), which is possible to discriminate from the LSPR response due to changes in bulk RI. In spite of the large LSPR shifts due to bulk refractive index, we show, using biotin-functionalized gold nanorods binding to streptavidin, that LSPR signal from gold nanorods embedded in the anionic hydrogel can be used for label-free biosensing. These results demonstrate the utility of immobilizing gold nanorods in a hydrogel on a double-clad optical fiber-end facet to obtain multi-parameter sensing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.